Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Drilon on the Utility of Brigatinib in ALK+ NSCLC

January 31st 2020

Alexander Drilon, MD, discusses the utility of brigatinib in ALK-positive non–small cell lung cancer.

Dr. Stinchcombe on the ALTA-1L Trial in ALK+ NSCLC

January 31st 2020

Thomas E. Stinchcombe, MD, discusses the results of the randomized phase III ALTA-1L trial in ALK-positive non–small cell lung cancer.

PD-L1: A Biomarker With Baggage

January 30th 2020

Although PD-L1 expression is the most established yardstick of response to immune checkpoint immunotherapy, its clinical utility as a biomarker remains an enigma further complicated by the variety of assays and algorithms for measuring it.

Dr. Gainor on Neoadjuvant Use of Biomarkers in Nonmetastatic Lung Cancer

January 30th 2020

Justin F. Gainor, MD, discusses a neoadjuvant use of biomarkers in nonmetastatic lung cancer.

FDA Schedules ODAC Meeting on Ramucirumab/Erlotinib in Frontline EGFR+ NSCLC

January 30th 2020

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application for intravenous ramucirumab injection for use in combination with erlotinib in the frontline treatment of patients with metastatic non–small cell lung cancer whose tumors harbor EGFR Ex19del or Ex21 substitution mutations.

FDA Grants Priority Review to Selpercatinib for RET Fusion+ NSCLC and Thyroid Cancers

January 29th 2020

The FDA has granted a priority review designation to a new drug application for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion–positive non–small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer.

Talking Tumors: Contemplating Clinical Conundrums in Lung Cancer

January 29th 2020

Lecia V. Sequist, MD, MPH, and Zofia Piotrowska, MD, MHS, give their input on how they approach cases that are often encountered in clinic.

Dr. Borghaei on Immunotherapy versus Chemotherapy and Immunotherapy in NSCLC

January 29th 2020

Hossein Borghaei, DO, MS, discusses immunotherapy alone or in combination with chemotherapy in combination with immunotherapy in patients with advanced NSCLC.

Dr. Bauml on the Utility of Liquid Biopsy in Metastatic NSCLC

January 28th 2020

Joshua Bauml, MD, discusses the utility of liquid biopsy in metastatic non–small cell lung cancer.

Dr. Yorio on Treatment Options for Patients With Rare Mutations in Metastatic Lung Cancer

January 28th 2020

Jeff Yorio, MD, discusses treatment options for patients with rare mutations in metastatic lung cancer.

"Ultrathin" Bronchoscopy Improves Care for Patients With Lung Nodules

January 27th 2020

To spare patients from surgery or other unnecessary procedures, Montefiore Einstein Center for Cancer Care developed an advanced method of bronchoscopy that provides peace of mind for individuals with lung nodules. The minimally invasive bronchoscopy provides a very safe method of biopsy, importantly at very early stages when the nodules are relatively small.

Dr. Saxena on the Importance of Initial Treatment Selection in ALK+ NSCLC

January 24th 2020

Ashish Saxena, MD, PhD, discusses the importance of initial therapy selection in ALK-positive non–small cell lung cancer.

Dr. Drilon on the Utility of Immunotherapy in ALK+ NSCLC

January 24th 2020

Alexander Drilon, MD, discusses the potential utility of immunotherapy in ALK fusion-positive non–small cell lung cancer.

NICE Recommends Against Frontline Osimertinib in EGFR-Mutant NSCLC

January 23rd 2020

The United Kingdom’s National Institute for Health and Care Excellence will not recommend osimertinib as a frontline treatment for patients with locally advanced or metastatic EGFR-mutant non–small cell lung cancer.

Dr. Herbst on Combination of Nivolumab and Ipilimumab in Patients With NSCLC

January 22nd 2020

Roy S. Herbst, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced non–small-cell lung cancer (NSCLC).

Dr. Stinchcombe on Molecular Testing in ALK+ NSCLC

January 22nd 2020

Thomas E. Stinchcombe, MD, discusses the importance of molecular testing in ALK-positive non–small cell lung cancer.

Tislelizumab Frontline Combos Improve PFS in Squamous NSCLC

January 21st 2020

The anti–PD-1 agent tislelizumab (BGB-A317) in combination with chemotherapy improved progression-free survival compared with chemotherapy alone as a first-line treatment for patients with advanced squamous non–small cell lung cancer.

FDA Approvals Boost Competition in Treatment Landscapes

January 18th 2020

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

Dr. Rotow on Updated ALEX Trial Results in ALK+ NSCLC

January 17th 2020

Julia Rotow, MD, discusses updated data from the phase III ALEX trial in ALK-positive non–small cell lung cancer.

Neural "Fingerprint" Enables Personalized SBRT Dose for Lung Cancer

January 14th 2020

A prognostic, deep-learning model developed by investigators at Cleveland Clinic’s Taussig Cancer Institute in Ohio and collaborators brings radiation oncology into the realm of personalized medicine.